- ANDEMBRY ®, the first and only once-monthly treatment targeting factor XIIa to prevent attacks in HAE patients, inhibits plasma protein factor XIIa, which initiates the cascade of events leading to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback